Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 10/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 6/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6756864 | 1.00 | HCAR2 (0.46) | HCAR2HCAR3CYP1A2MAOBALOX5 | |
| SCHEMBL6753774 | 0.88 | HCAR2 (0.46) | HCAR2HCAR3CYP1A2MAOBALOX5 | |
| SCHEMBL6753771 | 0.88 | HCAR2 (0.46) | HCAR2HCAR3CYP1A2MAOBALOX5 | |
| SCHEMBL9868083 | 0.81 | ALOX5 (0.40) | HCAR2HCAR3MAOBALOX5MAPT | |
| SCHEMBL9868087 | 0.81 | ALOX5 (0.40) | HCAR2HCAR3MAOBALOX5MAPT | |
| SCHEMBL9867033 | 0.79 | HCAR2 (0.47) | HCAR2HCAR3CYP1A2MAOBNPC1 | |
| SCHEMBL9867025 | 0.79 | HCAR2 (0.47) | HCAR2HCAR3CYP1A2MAOBNPC1 | |
| SCHEMBL7252811 | 0.77 | HCAR2 (0.55) | HCAR2HCAR3CYP1A2 | |
| SCHEMBL7252802 | 0.77 | HCAR2 (0.55) | HCAR2HCAR3CYP1A2 | |
| SCHEMBL7252809 | 0.77 | HCAR2 (0.55) | HCAR2HCAR3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5017601-A | Anti-ulcer 5-(2-substituted ethenyl)-3(2H)-furanones | AMERICAN HOME PRODUCTS CORPORATION (US) | 1991-05-21 | — | — | US | claimed |
| US-6710078-B2 | ANTITUMOR, ANTICANCER AGENTS | WYETH HOLDINGS CORPORATION | 2004-03-23 | — | — | US | disclosed |
| US-20030073736-A1 | 5-Substituted-3(2H)-furanones useful for inhibition of farnesyl-protein transferase | AMERICAN CYANAMID COMPANY | 2003-04-17 | — | — | US | disclosed |
| WO-2003018575-A1 | 5-SUBSTITUTED-3(2H)-FURANONES USEFUL FOR INHIBITION OF FARNESYL-PROTEIN TRANSFERASE | WYETH HOLDINGS CORPORATION (US) | 2003-03-06 | — | — | WO | disclosed |
| US-5017601-A | Anti-ulcer 5-(2-substituted ethenyl)-3(2H)-furanones | AMERICAN HOME PRODUCTS CORPORATION (US) | 1991-05-21 | — | — | US | disclosed |
| US-5010102-A | Anti-ulcer 5-(2-substituted ethenyl)-3(2H)-furanones | AMERICAN HOME PRODUCTS CORP. (US) | 1991-04-23 | — | — | US | disclosed |
| US-5001126-A | Anti-ulcer 5-(2-substituted ethenyl)-3(2H)-furanones | AMERICAN HOME PRODUCTS CORPORATION (US) | 1991-03-19 | — | — | US | disclosed |
| US-4966905-A | Anti-ulcer 5-(2-substituted ethenyl)-3-(2H)-furanones | AMERICAN HOME PRODUCTS CORPORATION (US) | 1990-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073736-A1 | 5-Substituted-3(2H)-furanones useful for inhibition of farnesyl-protein transferase | FNTB, FNTA, FDPS | HCAR2 4658/4885HCAR3 4173/4885CYP1A2 1274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.